Lentiviruses, a genus of retroviruses that can infect both dividing and non-dividing cells, have become invaluable tools in gene therapy due to this unique capability.
Before delving into the packaging process, it's crucial to understand the basics of the lentivirus life cycle. Lentiviruses, like HIV-1 (the most commonly used lentiviral vector system), carry their genetic information in the form of single-stranded RNA.
For gene therapy applications, the goal is to create lentiviral vectors that can deliver a therapeutic gene without replicating or causing disease. This is achieved through genome manipulation and the packaging system.
To ensure safety and efficient vector production, lentivirus packaging typically relies on a tripartite plasmid system.
The three essential plasmids are:
The Transfer Plasmid (or Vector Genome): This plasmid contains the therapeutic gene of interest, flanked by crucial lentiviral sequences necessary for packaging, reverse transcription, integration, and gene expression.
The Packaging Plasmid (or Gag-Pol Plasmid): This plasmid provides the genes necessary for the structural proteins (Gag) and enzymes (Pol, which includes reverse transcriptase, integrase, and protease) required for virion assembly and genome processing.
The Envelope Plasmid (or Env Plasmid): This plasmid encodes the viral envelope glycoprotein, which determines the tropism (the range of cell types the vector can infect).
Once the three plasmids are introduced into the producer cells, the following steps occur:
Transcription and Translation: The genes on the plasmids are transcribed into RNA and then translated into proteins. The transfer plasmid RNA contains the therapeutic gene and the necessary cis-acting sequences. The packaging plasmid produces the Gag and Pol proteins. The envelope plasmid produces the Env protein (e.g., VSV-G).
Assembly at the Plasma Membrane: The Gag polyprotein migrates to the plasma membrane, where it interacts with the transfer plasmid RNA (mediated by the ψ packaging signal) and the Env protein. The Gag polyprotein then assembles into an immature viral particle.
Genome Encapsidation: The ψ packaging signal on the transfer RNA specifically recruits the RNA into the assembling viral particle. This ensures that only the desired therapeutic gene construct is packaged, and not the RNAs transcribed from the packaging or envelope plasmids.
Budding and Release: The immature viral particles bud off from the producer cell membrane, acquiring the envelope protein during this process.
Maturation: After budding, the viral protease, encoded by the pol gene, becomes active and cleaves the Gag polyprotein into its mature structural components (matrix, capsid, and nucleocapsid proteins). This proteolytic processing is essential for the formation of a mature, infectious lentiviral particle. The Pol polyprotein is also processed into functional reverse transcriptase, integrase, and protease enzymes.
The resulting lentiviral particles are replication-defective because they lack the genes encoding the structural proteins and enzymes, which are provided in trans by the packaging plasmid in the producer cells. These harvested lentiviral vectors can then be used to transduce target cells, delivering the therapeutic gene for expression.
The tripartite plasmid system is a significant safety feature, greatly reducing the risk of generating RCLs. Further safety measures often include:
Self-inactivating (SIN) vectors: Modifications in the U3 region of the 3' LTR in the transfer plasmid lead to the inactivation of the LTR promoter after reverse transcription and integration in the target cell. This prevents transcriptional read-through and potential activation of nearby host genes.
Split packaging components: Some systems further divide the packaging functions onto even more plasmids to further reduce the chance of recombination events that could generate RCLs.
Use of heterologous viral components: Employing components from different retroviruses can further minimize the risk of recombination.
Lentivirus packaging is a sophisticated and carefully engineered process that lies at the heart of lentiviral vector-based gene therapy. The tripartite plasmid system allows for the safe and efficient production of replication-defective viral particles capable of delivering therapeutic genes for long-term expression in target cells. Ongoing advancements in vector design and packaging strategies continue to improve the safety, efficacy, and targeting capabilities of lentiviral vectors, paving the way for the treatment of an ever-expanding range of human diseases.
